Literature DB >> 15482377

Interactions between aspirin and COX-2 inhibitors or NSAIDs in a rat thrombosis model.

Anwar Umar1, Michel Boisseau, Abdiryim Yusup, Halmurat Upur, Bernard Bégaud, Nicholas Moore.   

Abstract

Recent in vitro studies, clinical trials and epidemiological studies have suggested possible interactions between aspirin and other cyclo-oxygenase (COX) inhibitors, such as ibuprofen of the COX-2 inhibitors celecoxib and rofecoxib. The objective of this study was to test the effects of aspirin (1, 2.5 and 5 mg/kg), and ibuprofen (4 and 15 mg/kg), diclofenac (2.5 mg/kg), flurbiprofen (2 mg/kg), celecoxib (7.5 mg/kg), and rofecoxib (1 mg/kg), alone or combined on a rat model of arterial thrombosis. Drugs were given orally daily for 7 days, before insertion of an arterio-venous shunt thrombosis system, left in place for 15 min. Main parameter was thrombus weight. Five to 12 rats were used per experiment, and 35 controls overall. Aspirin inhibited thrombus formation in a dose-dependent manner. All NSAIDS given alone also inhibited thrombus formation to approximately the same level as aspirin 1 mg/kg/day. Ibuprofen, celecoxib and rofecoxib inhibited the effects of aspirin, but not diclofenac or flurbiprofen. The interactions with aspirin do not seem to affect all NSAIDs to equal levels. The clinical impact of this needs to be confirmed in adequately powered clinical trials or pharmaco-epidemiological studies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15482377     DOI: 10.1111/j.1472-8206.2004.00285.x

Source DB:  PubMed          Journal:  Fundam Clin Pharmacol        ISSN: 0767-3981            Impact factor:   2.748


  4 in total

1.  Chebulagic acid inhibits the LPS-induced expression of TNF-α and IL-1β in endothelial cells by suppressing MAPK activation.

Authors:  Yueying Liu; Luer Bao; Liying Xuan; Baohua Song; Lin Lin; Hao Han
Journal:  Exp Ther Med       Date:  2015-04-23       Impact factor: 2.447

Review 2.  Coronary Risks Associated with Diclofenac and Other NSAIDs: An Update.

Authors:  Nicholas Moore
Journal:  Drug Saf       Date:  2020-04       Impact factor: 5.606

3.  A Novel Direct Factor Xa Inhibitory Peptide with Anti-Platelet Aggregation Activity from Agkistrodon acutus Venom Hydrolysates.

Authors:  Meimei Chen; Xiaohui Ye; Xin Ming; Yahui Chen; Ying Wang; Xingli Su; Wen Su; Yi Kong
Journal:  Sci Rep       Date:  2015-06-02       Impact factor: 4.379

4.  Effects of danshensu on platelet aggregation and thrombosis: in vivo arteriovenous shunt and venous thrombosis models in rats.

Authors:  Chen Yu; Dong Qi; Wei Lian; Qing-Zhong Li; Hong-Juan Li; Hua-Ying Fan
Journal:  PLoS One       Date:  2014-11-06       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.